Literature DB >> 15757806

Serological markers of liver cancer.

Man-Fung Yuen1, Ching-Lung Lai.   

Abstract

Serological markers for hepatocellular carcinoma (HCC) are important for early diagnosis, as well as monitoring of tumour aggressiveness, treatment responsiveness, recurrence and survival. The three most common markers are total alpha-fetoprotein (AFP), Lens culinaris agglutinin-reactive AFP (AFP-L3) and protein induced by vitamin K absence or antagonist-II (PIVKA-II). Total AFP has the sensitivity of 60% and specificity of 90% for the detection of HCC. Increase in the percentage of AFP-L3 over the total AFP (>10%) is very specific for small HCC. PIVKA-II is also more specific than total AFP in detecting HCC. AFP-L3 and PIVKA-II levels correlate with tumour aggressiveness and prognosis. All three markers are useful for monitoring treatment responsiveness and tumour recurrence. Since the levels of the three markers are independent of each other, combination of measurement of two or three markers will increase the sensitivity and diagnostic accuracy. Some novel markers including glypican-3 are being extensively studied.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15757806     DOI: 10.1016/j.bpg.2004.10.003

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  29 in total

1.  Hepatocellular Carcinoma in an HIV Patient "Cured" of Hepatitis C Virus.

Authors:  Arun Swaminath
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-08

2.  Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma.

Authors:  Robert G Gish; Ghassan K Abou-Alfa; Myron J Tong
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-09

3.  AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC.

Authors:  Kentaroh Yamamoto; Hiroshi Imamura; Yutaka Matsuyama; Yukio Kume; Hitoshi Ikeda; Gary L Norman; Zakera Shums; Taku Aoki; Kiyoshi Hasegawa; Yoshifumi Beck; Yasuhiko Sugawara; Norihiro Kokudo
Journal:  J Gastroenterol       Date:  2010-07-13       Impact factor: 7.527

4.  Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma.

Authors:  G Treiber; T Wex; C Röcken; P Fostitsch; P Malfertheiner
Journal:  J Cancer Res Clin Oncol       Date:  2006-07-12       Impact factor: 4.553

Review 5.  Diagnosis of hepatocellular carcinoma.

Authors:  Asmaa I Gomaa; Shahid A Khan; Edward L S Leen; Imam Waked; Simon D Taylor-Robinson
Journal:  World J Gastroenterol       Date:  2009-03-21       Impact factor: 5.742

6.  A New Generation Prothrombin Time Method for INR.

Authors:  Juha Horsti; Helena Uppa; Juhani A Vilpo
Journal:  Open Med Chem J       Date:  2008-02-27

7.  Protrusion-localized STAT3 mRNA promotes metastasis of highly metastatic hepatocellular carcinoma cells in vitro.

Authors:  Yan-Hong Liu; Jia-Lu Jin; Yu-Zhe Wang; Ying Tan; Ying-Ying Zhou; Ting Peng; Feng Li; Wan-Dong Liang; Pascal Chartrand; Yu-Yang Jiang; Zhi-Fa Shen
Journal:  Acta Pharmacol Sin       Date:  2016-05-02       Impact factor: 6.150

8.  MiR-22 regulated T cell differentiation and hepatocellular carcinoma growth by directly targeting Jarid2.

Authors:  Lian Zhang; Ping Yang; Jing Wang; Qi Liu; Tian Wang; Yaling Wang; Feng Lin
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

9.  Diagnosis of a previously unidentified primary site in patients with spinal metastasis: diagnostic usefulness of laboratory analysis, CT scanning and CT-guided biopsy.

Authors:  Yoichi Iizuka; Haku Iizuka; Satoshi Tsutsumi; Yumi Nakagawa; Takashi Nakajima; Yasunori Sorimachi; Tsuyoshi Ara; Masahiro Nishinome; Takayuki Seki; Kenji Takagishi
Journal:  Eur Spine J       Date:  2009-06-16       Impact factor: 3.134

10.  Alpha-fetoprotein: from a diagnostic biomarker to a key role in female fertility.

Authors:  Christelle De Mees; Julie Bakker; Josiane Szpirer; Claude Szpirer
Journal:  Biomark Insights       Date:  2007-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.